Generalized Anxiety Risk and Your Genetics

Generalized Anxiety Risk is a polygenic trait reflecting inherited susceptibility to generalized anxiety disorder (GAD), a condition characterized by persistent, excessive worry about everyday situations. Research using large population datasets has identified multiple genomic loci associated with GAD risk, implicating genes active in brain development and synaptic function. [¹] This page covers what the current genetic evidence shows, which genes are implicated, and how to interpret your ExomeDNA score in everyday context.

What is Generalized Anxiety Risk?

Generalized anxiety disorder is defined by chronic, difficult-to-control worry that is disproportionate to the actual likelihood or impact of anticipated events, lasting at least six months and occurring across multiple areas of life. Unlike fear tied to a specific trigger, GAD produces a diffuse, free-floating apprehension that can affect sleep, concentration, physical comfort, and the ability to carry out daily tasks.

GAD is one of the most common mental health conditions globally, affecting people across all demographic groups. Its causes are understood to be multifactorial: genetics, early-life environment, chronic stress, and neurobiological factors all contribute. The heritable component of GAD — the proportion of variation in susceptibility that can be traced to inherited genetic differences between people — has motivated large-scale genomic research aimed at identifying specific variants and the biological pathways they influence.

Your ExomeDNA Generalized Anxiety Risk score summarizes the cumulative influence of common genetic variants associated with GAD in population-level research. A higher score reflects carrying more of these variants, not a certainty of developing the condition. Environmental factors, life history, and protective influences all interact with genetic predisposition to determine actual outcomes.

The genetics behind Generalized Anxiety Risk

GAD is a polygenic trait, meaning that many genetic variants — each individually small in effect — combine across the genome to shape susceptibility. No single gene causes GAD; instead, the collective signal from dozens to hundreds of common variants contributes to a person's inherited risk profile.

Genetic research has identified associations near several genes with biologically plausible roles in brain function and neural connectivity. Among the strongest signals are variants near LAMC3, which encodes a component of laminin, an extracellular matrix protein important for brain cortical development and neuronal layering. Variants near TMEM106B have also shown a high-confidence association; TMEM106B is expressed in neurons and plays a role in lysosomal function and synaptic maintenance, with prior links to neurological traits.

MAPT and its intronic transcript MAPT-IT1 represent another region of interest. MAPT encodes the microtubule-associated protein tau, a structural protein important for axonal stability and intracellular transport in neurons. Dysregulation of tau-related pathways has broad implications for neuronal function beyond neurodegenerative contexts, and the MAPT locus appears repeatedly in psychiatric genetics research.

MAD1L1, which encodes a component of the mitotic arrest deficient complex involved in cell cycle regulation, has shown a medium-confidence association with GAD. Its neurological relevance is an active area of research. SOX6 encodes a transcription factor with well-established roles in interneuron differentiation — the class of inhibitory neurons that modulate excitatory signaling in the cortex and are implicated in anxiety-related neural circuits.

CTNNA1 encodes alpha-catenin, a protein that connects cell-surface cadherins to the actin cytoskeleton and plays an important role in cell adhesion. In the nervous system, cadherin-catenin complexes are critical for synaptic organization and the structural integrity of neuronal connections. IGSF9B is predicted to be involved in synaptic membrane adhesion and homophilic cell adhesion via plasma membrane adhesion molecules — functions that shape how neurons form and maintain contacts with one another.

Additional associated genes include LRFN5, involved in synaptic scaffolding, and VWDE, a von Willebrand factor domain-containing gene with expression in the brain. Taken together, the implicated genes converge on themes of synaptic structure, neural circuit development, and cortical organization — consistent with the hypothesis that GAD has partly neurodevelopmental origins.

What the research says

Research base: Moderate.

A key study advancing the genetics of GAD used a phenotype risk score (PheRS) approach applied to UK Biobank data. [¹] Because many biobank participants had not completed formal mental health assessments, researchers applied elastic net regression to predict GAD, posttraumatic stress disorder, and major depression symptoms in approximately 69% of participants who lacked direct phenotypic data — substantially expanding the effective sample size available for genomic analysis. [¹]

Meta-analyses combining predicted and directly assessed phenotypes identified 13 novel genomic risk loci for GAD. [¹] This represented a meaningful expansion of the known genetic architecture of GAD, which had been difficult to study due to the historically smaller sample sizes available for psychiatric GWAS compared to conditions with broader biobank phenotyping.

13 novel genomic loci for GAD were identified through meta-analysis combining predicted and directly assessed phenotypes in UK Biobank participants, using a phenotype risk score approach to expand effective sample size.^[¹]

Transcriptomic analyses within the same research effort implicated altered regulation of the prenatal dorsolateral prefrontal cortex as a biological mechanism shared between GAD and PTSD. [¹] The dorsolateral prefrontal cortex (dlPFC) is a region central to executive function, emotional regulation, and working memory — functions that are often disrupted in anxiety disorders. The fact that these transcriptomic signals were strongest during prenatal development points toward neurodevelopmental origins, suggesting that some of the genetic risk for GAD acts during early brain formation rather than only in response to adult stressors.

Prenatal dorsolateral prefrontal cortex regulation was implicated by transcriptomic analyses, pointing to neurodevelopmental biological mechanisms shared between generalized anxiety disorder and PTSD.^[¹]

The moderate confidence tier for this trait reflects that the genetic evidence is grounded in robust methodology and a large population study, but GAD's polygenic architecture means that no single genomic region dominates the signal, and further replication across diverse ancestries continues to refine the picture.

See our methodology page for how ExomeDNA assesses genetic evidence.

How Generalized Anxiety Risk affects you

A higher Generalized Anxiety Risk score means you carry more of the common genetic variants statistically associated with GAD susceptibility in large population studies. In practical terms, this may reflect a lower neurobiological threshold for anxiety responses — not a fixed destiny, but a predisposition that interacts with everything else in your life.

Genetics explains part of why some people find certain experiences more anxiety-provoking than others, and why anxiety symptoms can seem to run in families even when life circumstances appear similar. People with a higher genetic loading for GAD may find that their nervous systems respond more strongly to uncertainty, interpersonal conflict, health concerns, or work demands — the classic worry domains associated with generalized anxiety.

It is important to emphasize what a genetic score does not capture: the full range of factors that determine whether GAD develops and how it presents. Adverse childhood experiences, trauma, social support, coping strategies, sleep quality, exercise habits, and access to care all shape outcomes in ways that your DNA cannot predict. Many people with high genetic risk never develop clinical anxiety; many people with low genetic risk do, given the right (or wrong) circumstances.

The value of understanding your genetic profile lies not in predicting the future but in helping you make sense of tendencies you may already recognize in yourself — and in prompting proactive conversations with healthcare providers about monitoring and support.

Working with your Generalized Anxiety Risk profile

Genetic knowledge is most useful when it motivates action, not fatalism. If you carry elevated genetic susceptibility to GAD, there are well-established ways to support your mental and neurological health that do not require waiting for symptoms to become problematic.

Sleep architecture is a primary modifiable factor. Sleep disruption both triggers and maintains anxiety, and the prefrontal cortex regions implicated in GAD genetics are among the brain areas most sensitive to sleep deprivation. Prioritizing consistent sleep timing and duration is among the highest-leverage behavioral investments for people with anxiety-related genetic profiles.

Aerobic exercise has documented effects on GAD symptoms and neurobiological markers relevant to anxiety, including effects on prefrontal cortex function and inhibitory neurotransmission. Regular moderate exercise — most days of the week — is supported by substantial evidence as a non-pharmacological approach to reducing anxiety vulnerability.

Cognitive patterns and therapeutic support matter independently of genetics. Cognitive behavioral therapy (CBT) has a strong evidence base for GAD and works by restructuring the thought patterns that sustain chronic worry. Knowing that you may carry elevated genetic susceptibility is a reasonable basis for discussing preventive or early-intervention options with a mental health professional — particularly if you recognize worry patterns in your daily life.

Stress load management — deliberately limiting the accumulation of unresolved stressors — is relevant for people whose nervous systems may be tuned toward higher sensitivity. This includes prioritizing commitments, building recovery time into schedules, and developing explicit strategies for handling uncertainty.

This information is not a substitute for evaluation or support from a qualified mental health professional. If anxiety is affecting your daily life, a clinician is the right starting point.

Related traits and genes

Generalized anxiety disorder shares genetic architecture with several related traits, reflecting the overlapping biology of stress, mood, and emotional regulation.

Depression Risk is genetically correlated with GAD; the two conditions co-occur frequently, and some of the same genomic loci contribute to both. PTSD Risk shares genetic signals with GAD, including the prenatal prefrontal cortex transcriptomic signature identified in the same research. [¹] Neuroticism Score captures a broader personality dimension of emotional reactivity that overlaps with GAD susceptibility at the genetic level.

Cross-category traits with relevant genetic connections include Sleep Quality, given the bidirectional relationship between sleep architecture and anxiety neurobiology, and Stress Response, which reflects related but distinct aspects of the autonomic nervous system's reaction to threat.

The gene with the strongest evidence for GAD association in this trait profile, LAMC3, is explored in more detail on the LAMC3 gene page. LAMC3 encodes a laminin subunit critical for cortical neuronal organization, and its connection to anxiety-related traits points to the role of the extracellular matrix in establishing the brain architecture that supports emotional regulation.

Other genes in this trait's profile — including TMEM106B (synaptic maintenance and lysosomal function), MAPT (axonal structural integrity), SOX6 (inhibitory interneuron development), and CTNNA1 (synaptic cell adhesion) — each represent a different facet of the neural biology underlying anxiety susceptibility.

Frequently asked questions

Can a DNA test tell me whether I have generalized anxiety disorder? No. Genetic testing cannot tell you whether you currently have or will develop generalized anxiety disorder. Your ExomeDNA score reflects the combined influence of common genetic variants linked to GAD susceptibility at the population level — it is one input among many, not a clinical determination.

What does a higher Generalized Anxiety Risk score mean for me? A higher score means you carry a greater number of common genetic variants statistically associated with generalized anxiety disorder in large population studies. It does not mean anxiety is certain — environment, life experience, and other biological factors all play substantial roles in whether GAD develops.

What is a phenotype risk score and how does it relate to GAD? A phenotype risk score (PheRS) is a statistical tool that combines information from multiple health indicators to estimate the likelihood of a condition. For GAD, researchers used PheRS to expand effective study sample sizes by estimating anxiety-related phenotypes in people who had not completed formal mental health assessments, then identified new genomic loci associated with that predicted phenotype. [¹]

Which genes are linked to generalized anxiety disorder in genetic research? Large-scale genetic studies have identified variants near genes including LAMC3, TMEM106B, MAPT, MAD1L1, SOX6, CTNNA1, IGSF9B, LRFN5, VWDE, and MAPT-IT1 as associated with generalized anxiety disorder risk. Many of these genes have roles in brain development, synaptic structure, and neuronal connectivity. [¹]

Is generalized anxiety disorder entirely genetic? No. GAD is influenced by a combination of genetic and non-genetic factors. Common genetic variants explain only a portion of the variation in GAD susceptibility across populations. Childhood experiences, chronic stress, trauma, sleep patterns, and social support are among the many non-genetic contributors.

What part of the brain is implicated in the genetics of GAD? Transcriptomic analyses in genetic research on GAD have implicated altered regulation of the prenatal dorsolateral prefrontal cortex — a brain region involved in executive function, emotional regulation, and working memory. This points toward neurodevelopmental biological mechanisms that may shape long-term anxiety susceptibility. [¹]

How does ExomeDNA's Generalized Anxiety Risk score differ from a clinical anxiety assessment? Clinical anxiety assessments rely on structured interviews, clinician judgment, symptom duration, and functional impact. ExomeDNA's score is derived entirely from common genetic variants identified in population-level research and captures inherited predisposition only. The two approaches measure different things and are not interchangeable.

References

[1] Wendt FR, Pathak GA, Deak JD, De Angelis F, Koller D, Cabrera-Mendoza B, Lebovitch DS, Levey DF, Stein MB, Kranzler HR, Koenen KC, Gelernter J, Huckins LM, Polimanti R. Using phenotype risk scores to enhance gene discovery for generalized anxiety disorder and posttraumatic stress disorder. Molecular Psychiatry. 2022;27(4):2206-2215. PMID: 35181757. DOI: 10.1038/s41380-022-01469-y

Data sources: Genetic association data draws on GWAS findings reported in the above peer-reviewed publication. Gene function annotations draw on NCBI Gene summaries for CTNNA1 and IGSF9B. Locus-to-gene evidence is used internally to prioritize candidate genes for annotation; specific scoring methods are not named in consumer content per ExomeDNA methodology standards.

By the ExomeDNA Research Team